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In Copenhagen, methicillin-resistant Staphylococcus 
aureus (MRSA) accounted for <15 isolates per year during 
1980–2002. However, since 2003 an epidemic increase has 
been observed, with 33 MRSA cases in 2003 and 110 in 
2004. We analyzed these 143 cases epidemiologically and 
characterized isolates by pulsed-ﬁ  eld gel electrophoresis, 
Staphylococcus protein A (spa) typing, multilocus sequence 
typing, staphylococcal chromosome cassette (SCC) mec 
typing, and detection of Panton-Valentine leukocidin (PVL) 
genes. Seventy-one percent of cases were community-
onset MRSA (CO-MRSA); of these, 36% had no identiﬁ  ed 
risk factors. We identiﬁ  ed 29 spa types (t) and 16 sequence 
types (STs) belonging to 8 clonal complexes and 3 ST sin-
gletons. The most common clonal types were t024/ST8-IV, 
t019/ST30-IV, t044/ST80-IV, and t008/ST8-IV (USA300). A 
total of 86% of isolates harbored SCCmec IV, and 44% had 
PVL. Skin and soft tissue infections dominated. CO-MRSA 
with diverse genetic backgrounds is rapidly emerging in a 
low MRSA prevalence area.
F
or many years, methicillin-resistant Staphylococcus au-
reus (MRSA) has been a serious and common nosoco-
mial pathogen in hospitals outside the Nordic countries and 
the Netherlands (1). Community-onset MRSA (CO-MRSA) 
was ﬁ  rst reported in Western Australia in the early 1990s 
(2) and has, especially during the past 5 years, emerged as 
a global problem (1,3). CO-MRSA in the United States has 
mostly been caused by the Panton-Valentine leukocidin 
(PVL)–positive clones USA400 (sequence type [ST]1) and 
more recently by USA300 (ST8) (1,4–7). In Europe the in-
crease in CO-MRSA has mostly been attributed to the PVL-
positive ST80 clone (3,8). In Denmark, since 1980, MRSA 
has accounted for <100 MRSA isolates per year nationwide 
(www.danmap.org/pdfﬁ  les/danmap_2005.pdf). At our labo-
ratory, MRSA has been isolated from <15 patients per year 
until 2002. Approximately half of the MRSA cases found 
in Denmark during these years were imported, i.e., through 
patients transferred from foreign hospitals (9).
Since 2003 the number of MRSA-positive persons in-
creased both nationally and in Copenhagen. Nationally, the 
number increased from 50–105 new cases per year to 243 
in 2003, 549 in 2004, and 864 in 2005. At Hvidovre Hos-
pital, we found MRSA in 5 persons in 2001, 14 in 2002, 
33 in 2003, 110 in 2004, and 170 in 2005. We describe the 
epidemiology of the emergence of MRSA in Copenhagen 
in 2003 and 2004 and characterize the genetic background 
of the isolates.
Materials and Methods
Setting
The Department of Clinical Microbiology, Hvidovre 
Hospital, services 4 of the 5 hospitals in Copenhagen and 
receives all microbiology samples from general practice 
in the Copenhagen and Frederiksberg Municipality (pop-
ulation 597,000). The total number of swabs received in 
the laboratory decreased slightly from 60,245 in 2000 to 
55,223 in 2004. The principles for MRSA treatment, iso-
lation of all hospitalized MRSA patients and hospital and 
household screening, were not changed before or during 
the study period. The only change was the introduction of 
new molecular typing methods.
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Patient Data
Upon identiﬁ  cation of an MRSA isolate, the patient’s 
attending physician was contacted to ensure correct anti-
microbial chemotherapy and isolation procedures. The 
patient’s physician was interviewed about the patient to 
deﬁ  ne types of infections, identify risk factors, and estab-
lish epidemiologic links between patients. Most interviews 
were followed up by 1–5 more contacts. All interview data 
were registered prospectively in case-report forms and en-
tered into the patient record ﬁ  les of our laboratory informa-
tion system. The National Health Care Database (NHCD) 
was used to check for hospital admissions and ambulatory 
healthcare visits in Danish hospitals within the previous 2 
years. These data enabled us to identify whether MRSA 
patients had been hospitalized in the same ward during 
the same period. The patients’ home addresses, household 
members, and their general practitioners were identiﬁ  ed 
in the NHCD. The patients were divided into 4 groups 
of acquisition mode of MRSA (8): 1) hospital-acquired 
(HA)–MRSA, MRSA isolated in a sample taken >48 h 
after admission or known exposure in a Danish hospital 
(domestic HA-MRSA) or a hospital abroad (imported HA-
MRSA); 2) community-onset MRSA healthcare-associated 
(CO-HCA), MRSA isolated in a sample taken <48 hours 
after hospital admission or in general practice, with hospi-
talization and/or outpatient treatment in the previous year, 
having close contact to a person with HA-MRSA, residing 
in a nursing home, receiving in-home help or home nurs-
ing, being on dialysis, having cancer or diabetes, or being 
a drug abuser; 3) CO-MRSA community risk (CO-CR), 
MRSA isolated in a sample taken <48 hours after hospital 
admission or in general practice and having close contact 
to a person with CO-MRSA or having recently traveled to 
a country with high MRSA endemicity (no known contact 
with healthcare); and 4) CO-MRSA with no known risk 
factors (CO-NR), MRSA isolated in a sample taken <48 
hours after hospital admission or in general practice, with 
no healthcare association, no known community risk, and 
no travel risk.
MRSA Isolates and Antimicrobial Susceptibility Testing
S. aureus isolates were identiﬁ  ed by positive Staph-
aurex (Remel Europe Ltd., Dartford, UK) result and a posi-
tive coagulase test result. Only the ﬁ  rst MRSA isolate from 
each patient was included in our study, for a total of 143 
isolates in 2003 and 2004.
Susceptibility testing was performed on Isosensitest 
agar by the disk-diffusion method (antibiotic disks; Ox-
oid, Basingstoke, UK) according to recommendations of 
the Swedish Reference Group for Antibiotics (www.srga.
org). Isolates were screened for resistance to methicillin 
by a cefoxitin 10-μg disk (10). Isolates were further tested 
against penicillin, cefuroxime, erythromycin, clindamycin, 
gentamicin, vancomycin, fucidic acid, rifampin, tetracy-
cline, and moxiﬂ  oxacin. Inducible clindamycin resistance 
was examined by using the double-disk method (11). All 
MRSA isolates were conﬁ  rmed mecA positive by PCR 
(12). Multidrug-resistant MRSA was deﬁ  ned as an isolate 
resistant to >3 non–β-lactam antimicrobial agents.
Typing Methods
SmaI macrorestriction proﬁ   les were performed ac-
cording to the HARMONY protocol (13) and analyzed 
with Bionumerics version 4.5 software (Applied Maths, 
Kortrijk, Belgium). Concatamerized phage λ DNA (New 
England Biolabs, Ipswich, MA, USA) was loaded in every 
sixth lane as a molecular weight standard to normalize the 
individual gels, and SmaI-digested S. aureus NCTC 8325 
was used to normalize the gels to each other. Only DNA 
fragments in the range of the λ ladder (50–1,000 kb) were 
included in the analysis. Pulsed-ﬁ  eld gel electrophoresis 
(PFGE) clusters were identiﬁ  ed on an UPGMA (unweight-
ed pair-group method with arithmetic mean) dendrogram 
based on Dice coefﬁ  cients, where optimization and band 
position tolerance were set at 1% and 2%, respectively. 
A similarity coefﬁ  cient of 80% was selected to deﬁ  ne the 
clusters. Reference strains used for PFGE were USA100–
1100 (Centers for Disease Control and Prevention, Atlanta, 
GA, USA) and UK-MRSA 1, 3, 15, and 16 (HARMONY 
collection).
Sequencing of the staphylococcal protein A gene (spa 
typing) and multilocus sequence typing (MLST) were per-
formed as previously described (14,15), except that PCR 
products were enzymatically puriﬁ  ed with exonuclease I 
(New England Biolabs) and shrimp alkaline phosphatase 
(Amersham Biosciences, Piscataway, NJ, USA) before spa 
sequencing. Sequence reactions were performed on both 
DNA strands and analyzed on an ABI Prism 3100 (Applied 
Biosystems, Foster City, CA, USA). For PCR and sequenc-
ing of the spa gene, primers 1113F and 1496R were used. 
Designation of spa type was conducted by using the Ridom 
StaphType program (www.ridom.de) (16). MLST was per-
formed on 57 (40%) of the 143 isolates, representing all 
spa types, and on every ﬁ  fth randomly chosen isolate if the 
spa type was t024, t019, t044, or t008. STs and clonal com-
plexes (CCs) were assigned through the MLST database 
(www.mlst.net).
Staphylococcal chromosome cassette (SCC) mec 
types were determined by an in-house multiplex PCR strat-
egy in which types I–V were identiﬁ  ed (17). Presence of 
PVL determinants was detected by PCR by using primers 
that overlap with previously published primer sequences 
(18,19). Primer sequences were forward 5′-TAG-GTA-
AAA-TGT-CTG-GAC-ATG-3′ and reverse 5′-GCA-TCA-
AST-GTA-TTG-GAT-AGC-3′.
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Results
Patient and Infection Characteristics
In 2003 and 2004, 33 and 110 new cases of MRSA, 
respectively, were found. In 126 cases (88%) MRSA was 
from infection, and in 17 cases (12%) MRSA was found 
through screening of close family or hospital contacts to 
known MRSA patients.
Of the 143 MRSA cases, 42 (29%) were HA; 5 (3%) 
were imported, and 101 (71%) were CO. In 36 of the 101 
CO-MRSA cases, the patient had a healthcare risk (CO-
HCA), primarily due to hospitalization during the past year 
(21 cases) or residency in a nursing home (14 cases). Seven 
of the 36 patients were identiﬁ  ed during the ﬁ  rst 48 hours 
of hospitalization. For 30 patients a community risk (CO-
CR) was identiﬁ  ed, and for 35, no risk factors (CO-NR) 
were identiﬁ  ed.
MRSA was found in samples from 50 patients during 
their hospitalization. Seventeen of these patients were in 
single-bed rooms; for those in shared rooms, we had no 
data on possible roommates for 5 case-patients, and the 
roommates of 3 case-patients were not screened. For 21 
case-patients, MRSA screening of roommates was per-
formed. Screening showed 4 MRSA-positive roommates 
with MRSA strains of the same spa type as that of the in-
dex patient (3 t024, 1 t015). In 1 intensive care unit case, 
transmission presumably occurred from staff to a patient in 
an adjoining room, as the spa type found (t003) was unique 
among our isolates.
Transmission among the 93 patients that were not hos-
pitalized was more common. Of these, 11 resided in nurs-
ing homes; 5 were in the same nursing home. Another 14 
patients lived alone. For 15 patients it was not possible ret-
rospectively to determine whether anyone had lived with 
the patient (in most cases the index patient had died). In 
the households of 11 index patients, another 13 persons 
were found to be MRSA positive. The spa type most often 
found in family members was t019/ST30. In 11 families, 
all household members were MRSA negative. Household 
screening was not performed for 18 families.
Most of our MRSA cases were in the Amager re-
gion of Copenhagen. The 2-year incidence of CO-MRSA 
(HCA included) in Amager was 40:100,000 compared with 
12:100,000 in the rest of Copenhagen.
Skin and soft tissue infections dominated (91 [64%] of 
143 cases), followed by 17 urinary tract infections (UTIs, 
12%), 9 deep-seated abscesses (6%), 5 lower respiratory 
tract infections (LRTIs, 3%), and 4 cases of septicemia 
(3%) (Table 1; Figure). Patients with HA-MRSA and CO-
HCA MRSA had similar median ages: 78 (range 28–94 
years) and 82 years (6–95 years), respectively. The patients 
with CO-NR MRSA and CO-CR MRSA had median ages 
of 32 (range 0–90 years) and 27 years (1–74 years), re-
spectively (Table 1). The HA-MRSA and CO-HCA MRSA 
patients as well as the CO-NR MRSA and CO-CR MRSA 
patients were in many aspects similar and will be described 
as 1 group each.
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Table 1. Demographics, infection types, and distribution of MRSA types in 143 cases of MRSA* 
Community onset, 
community risk
Community onset, 
no risk
Hospital acquired in 
Denmark
Community onset, 
healthcare associated Imported
No. cases  30 35 37 36
Male, %  67 46 57 42
Median age, y (range)  27 (1–74) 32 (0–90) 80 (28–94) 82 (6–95)
Carrier, no.  8 1 2 2 4†
Type of infection, no. 
 SSTI    22 29 17 23
 Blood  0 0 2 2
Deep-seated abscess, no.  0 1 5 3
UTI 0 4 8 5
LRTI 0 0 3 1 1†
Four most common CCs (87% of all isolates) 
  CC 8, %  23 34 81 69
  t008,  no.  3 7 0 2
  t024,  no.  3 5 28 20
 CC  80,  %  20 34 3 0
 CC  30,  %  50 6 0 0
  CC 5, %  3 11 5 8
Other MLST types,%  4 15 11 23
PVL positive, %  83 80 8 17
SCCmec IV, %  93 89 89 81
*MRSA, methicillin-resistant Staphylococcus aureus; SSTI, skin and soft tissue infection; UTI, urinary tract infection; LRTI, lower respiratory tract infection; 
CC, clonal complex; MLST, multilocus sequence typing; PVL, Panton-Valentine leukocidin; SCC, staphylococcal chromosome cassette.
†A t037/ST239-III was imported from Greece, where this MRSA is common (20); ST239 is closely related to ST8 and is the well-known pandemic 
Brazilian/Hungarian clone (21); t041/ST111 was imported from an Italian hospital; t003/ST225-II (New York clone) was imported from Germany; 
t354/ST22-IV, a variant of EMRSA15, was imported from Lanzarote (Spain); and t067/ST125-I was imported from Spain.  RESEARCH
Susceptibility Testing of Isolates
Resistance to macrolides was detected in 85 (59%) of 
143 isolates and in all isolates of spa type t024 and 7 of 12 
t008 isolates. Constitutive macrolide resistance was found 
in 48% of erythromycin-resistant isolates. The resistance 
proﬁ  les of the 11 multiresistant isolates are described in the 
online Appendix Table (available from www.cdc.gov/EID/
content/13/10/1533-appT.htm) (3,8).
HA and CO-HCA MRSA
Of 11 multidrug-resistant MRSA, 8 belonged to this 
group. Resistance to β-lactams only was found in 6 CO-
HCA MRSA isolates (6 [8%] of 78) that belonged to 5 dif-
ferent CCs and contained either SCCmec IV or V.
CO-NR MRSA and CO-CR MRSA
Of 11 multidrug-resistant MRSA, 3 were in this group 
and 2 patients had no identiﬁ  ed risk factors (t002/CC5 and 
t044/ST80). Of 65 isolates, 23 (35%) were resistant only 
to β-lactams, and all contained SCCmec IV. More data on 
resistance can be seen in the online Appendix Table.
PFGE, spa Typing, and MLST
There was a strong overall match between the cluster-
ing based on PFGE dendrogram, spa type, ST, or CC of the 
analyzed isolates (Table 2; online Appendix Figure, avail-
able from www.cdc.gov/EID/content/13/10/1533-appG.
htm). The sequence-based typing methods showed 16 STs 
and 29 spa types (Table 2). MRSA isolates belonged to 8 
CCs; CC8 was the most frequent (Table 2). The most com-
mon ST was ST8, represented by 72 isolates. The dominant 
spa type was t024/ST8, which accounted for 56 (39%) of 
143 isolates. Other common MRSA were spa type t019/
ST30 (17 isolates), spa type t044/ST80 (16 isolates), and 
spa type t008/ST8 (12 isolates). The 5 imported MRSA be-
longed to CC5 (2 isolates), CC 8 (t037/ST239-III), CC 22, 
and ST111. One CC1 strain was placed far from the other 
2 CC1 isolates. The ﬁ  rst isolate was ST748, t127, PVL 
negative, and SCCmec V; the other 2 were ST1, t175, PVL 
positive, and SCCmec IV (USA400-like). PFGE could not 
discriminate between MRSA t008, PVL-positive isolates, 
and t024 PVL-negative isolates but intermingled these 
isolates.
HA and CO-HCA MRSA 
The 78 isolates (42 HA and 36 CO-HCA MRSA) rep-
resented 20 different spa types and 1 nontypeable isolate. 
A total of 48 (86%) of the 56 spa t024 were in this group. 
The patients were predominately elderly persons living in 
nursing homes or receiving home-care nursing. Most iso-
lates belonged to CC8 (72%) (Table 2). Thirty-seven of the 
HA-MRSA isolates were considered Danish nosocomial 
isolates (domestic HA-MRSA), and 5 were from patients 
transferred from foreign hospitals (imported HA-MRSA).
CO-NR MRSA and CO-CR MRSA
The 65 isolates (35 CO-NR-MRSA and 30 CO-CR 
MRSA) represented 12 different spa types. All of the 17 
t019/ST30, 15 of the 16 t044/ST80, and 10 of 12 of the 
t008/ST8 were found in this group. Only 8 patients with 
t024 were considered to have MRSA of CO-NR or CO-CR 
origin. Twenty-four cases were associated with household 
outbreaks, and transmission was suspected between chil-
dren in 2 kindergarten classes.
Distribution of SCCmec Types and 
Prevalence of PVL Genes
SCCmec Type
SCCmec types could be determined for 140 (98%) of 
143 isolates. SCCmec type IV was found in 122 (86%) of 
the isolates. Eighty-one percent of the HA and CO-HCA 
MRSA and 91% of the CO-NR/CO-CR isolates harbored 
SCCmec IV. The remaining isolates were represented by 
5 type I (3.5%), 5 type II (3.5%), 2 type III (1.5%), 6 type 
V (4%), and 3 nontypeable (NT) (2%). Five CCs contained 
>1 SCCmec type: CC1 had IV and V; CC5 had I, II and IV; 
CC8 had III, IV, and NT; CC22 had IV and NT; and CC 45 
had IV and V (Table 2).
PVL
Sixty-three (44%) MRSA isolates carried the PVL 
genes. Twenty-nine (97%) of 30 abscesses were caused by 
PVL-positive MRSA. PVL-positive isolates were also seen 
in 19 patients with chronic wounds, 8 MRSA carriers, 4   
patients with UTI, 1 patient with LRTI, 1 with ear infec-
tion, and 1 with pus from a gallbladder. spa types and PVL 
were clearly correlated: all t019/ST30, t044/ST80, t008/
ST8, t002/ST5, and t003/ST5 were positive for the PVL 
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Figure. Distribution of infection types in community-onset methicillin-
resistant  Staphylococcus aureus (MRSA) and hospital-acquired 
(HA) MRSA. HCA, healthcare associated; CO-NR, community-
onset MRSA with no identiﬁ   ed risk factors; CO-CR, community-
onset MRSA with community risk; SSTI, skin and soft tissue 
infection; LRTI, lower respiratory tract infection.MRSA, Copenhagen, Denmark
genes. The remaining PVL-positive isolates were found in 
the following spa types: t175 (2/2), t355 (1/1), t359 (1/1), 
t376 (2/2), and t455 (1/1). None of the 56 spa t024 carried 
the PVL genes (Table 2).
HA and CO-HCA MRSA
Ten (13%) of the 78 isolates were PVL-positive. Three 
of them were part of a hospital outbreak with spa t003 im-
ported in a patient from Germany.
CO-NR MRSA and CO-CR MRSA
Fifty-three (82%) PVL-positive isolates were found in 
the 65 strains in this group, 28 from patients with CO-NR 
MRSA and 25 from patients with CO-CR MRSA. PVL was 
present in 82% of CO-NR and CO-CR isolates, the iso-
lates that we regard as truly community-acquired MRSA 
isolates.
Discussion
The high degree of genetic diversity (in both MLST 
background and SCCmec cassettes) found among MRSA 
isolates from a low-prevalence area is of global public 
health concern. The number of MRSA isolates doubled in 
<1 year in our area. Had the spread continued unhindered, 
MRSA would very rapidly have become a major source of 
illness as well as a healthcare ﬁ  nancial concern for our hos-
pitals and in the community. Although national guidelines 
to prevent MRSA transmission were ﬁ  rst established in 
November 2006, an intervention program was introduced 
in Copenhagen in September 2005. We believe that our 
intervention program has had some effect: the number of 
cases in 2005 (170) increased to only 189 in 2006. While 
the current increase in CO-MRSA in the United States is 
predominantly by only 1 clone, USA300, we found 29 
different spa types and 16 different STs in an area of <50 
square miles. This ﬁ  nding suggests that the diversity has 
been caused not only by the spread of clones but also by 
the dissemination of the more mobile SCCmec elements 
IV and, to a lesser degree, V into methicillin-sensitive S. 
aureus (MSSA) (22). Typing MRSA with different meth-
ods gave additional information. The use of spa typing 
and PVL allowed the differentiation of MLST and PFGE 
identical isolates, and SCCmec typing could explain why 
MLST identical isolates had different PFGE patterns.
Our dominant clone, spa t024/ST8-IV, accounted 
for 39% of all isolates. The MRSA spa t024 clone is new 
in Denmark (8) and has been only sporadically reported, 
as MRSA or MSSA, to the SeqNet spa database (www.
spaserver.ridom.de). The t024 clone was PVL negative 
but carried SCCmec IV, as did the typical PVL-positive 
community clones t044/ST80, t019/ST30, and t008/ST8. 
t024 belongs to CC8, as did the archaic clone that caused 
hospital outbreaks in Denmark in the late 1960s and early 
1970s (23). The PFGE pattern of t024 is almost identical 
to that of t008 (USA300) but can be differentiated by be-
ing PVL negative and having a spa type that has lost 24 
consecutive bases (1 repeat). The PVL phenotype of t024 
CC8 strains was more like HA-MRSA around the globe. 
t024 was predominantly associated with nursing home out-
breaks and home care nursing in the same area of Copenha-
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Table 2. Genetic backgrounds and epidemiologic information on MRSA isolates* 
CC
Multilocus
ST Spa types
Isolates, no. 
(total in CC)
No. PVL-positive 
isolates
SCCmec types 
(no. isolates)
HA/HCA MRSA or CR/NR 
MRSA % in the CC
CC1 ST1
ST748†
t175
t127
2
1 (3)
2
0
IV
V
33/67
CC5 ST5
ST125
ST225
t002
t067
t003
7
1
4 (12)
7
0
4
I (3), II (1), IV(3) 
I
II
58/42
CC8 ST8
ST239
t024, t008, t430 
t064, t351 
t037
56/12/2
1/1
3 (75)
12 (t008) 
0
0
IV
IV
III (2), NT (1)
74/26
CC15 ST15 t084 1 0 V 100/0
CC22 ST22
ST737†
t005, t022, t354 
t541
t542
2/1/1
1
1 (6)
0
0
0
IV, NT (t022) 
IV
IV
50/50
CC30 ST30 t019 17 17 IV 0/100
CC45 ST45 t015, t026, t065 
t116, t350
2/1/1
1/1 (6)
0
0
IV, V (t026 and 
t116)
100/0
CC97 ST97 t359 1 1 V 100/0
Singleton ST80 t044, t376, t455 16/2/1 (19) 19 IV 5/95
Singleton ST111 t041 1 0 I 100/0
Singleton ST152 t355 1 1 V 0/100
Total 142 63
*MRSA, methicillin-resistant Staphylococcus aureus; CC, clonal complex; ST, sequence type; PVL, Panton-Valentine leukocidin; SCC, staphylococcal 
chromosome cassette; HA/HCA/CR/NR, hospital acquired/healthcare associated/community risk/no risk. One isolate could only be typed by spa and 
multilocus sequence typing and is not included in the table. 
†New ST. RESEARCH
gen as the nursing homes. Hospitalization of these patients 
led to small MRSA outbreaks. Our infection control team 
trained staff in the affected nursing homes in infection con-
trol. Isolation procedures in nursing homes were modiﬁ  ed, 
compared with hospital regimes, to respect the fact that the 
patients were living in their own home. The nursing home 
staff were predominantly social workers with rudimentary 
infection control education. This, combined with the fact 
that many patients were not eligible for eradication treat-
ment because of chronic wounds, could explain some of the 
difﬁ  culties in limiting the spread in nursing homes.
On the basis of spa typing, we have seen some evolu-
tion of the t024 clone. spa type t430 has evolved from t024 
by the loss of 24 consecutive bases. The 2 patients with 
t430 were identiﬁ  ed late in the t024 outbreak, and we ﬁ  nd 
it more likely that a deletion occurred in t024 rather than 
that a new MRSA clone was introduced or that the SCCmec 
was transmitted to MSSA. In support of this view, samples 
from 1 patient taken the same day had t024 (axilla sample) 
and t430 (nose sample) (data not shown).
Some of the internationally well-known CO-MRSA 
clones were among our isolates (3,24). Most of the t008/
ST8-IV could be identiﬁ  ed as MRSA USA300–0114 geno-
type on the basis of PFGE typing (data not shown) (25). 
This  ﬁ   nding is very troublesome because USA300 has 
evolved as the most rapidly spreading CO-MRSA in the 
United States and has become a dominant HA-MRSA in 
some hospitals (24). Special attention must be taken to con-
trol the spread of this clone. Sixteen (11%) isolates were 
t044/ST80-IV, which is a common CO-MRSA in Europe 
(3,26). This was a much more prevalent CO-MRSA clone 
in a national study of 81 Danish MRSA isolates from 2001, 
where 44% belonged to ST80-IV (8). We found that t019/
ST30-IV was the most common CO-MRSA (17 patients, 
12%). The t019/ST30-IV clone is known as the Southwest 
Paciﬁ  c clone, and many of our cases had a geographic link 
to the Far East (data not shown). t019 was PVL positive, 
generally susceptible to all non–β-lactams, and caused 
severe abscesses. The PVL-positive MRSA clones were 
almost never associated with hospital outbreaks probably 
because these patients with skin and soft tissue infections 
were rapidly discharged.
Our ﬁ  ndings of high prevalence of PVL-positive iso-
lates (44%) are not surprising and are consistent with data 
from other studies (27–29) in which PVL is associated with 
skin and soft tissue infections, commonly described in CO-
MRSA. Eighty-two percent of the CO-NR/CO-CR isolates 
contained the PVL genes, compared with only 13% of the 
HA/CO-HCA MRSA. We observed an age difference with 
a median age of 32 years (0–90 years) in the NR/CR group 
compared with 82 years (6–95 years) in the HCA group. 
These ﬁ  ndings might indicate that the ﬁ  rst group consists 
of patients with true community-onset MRSA and the sec-
ond group is closely related to our HA-MRSA. Current 
deﬁ  nitions are becoming of decreasing usefulness as typi-
cal CO-MRSA strains invade hospitals.
A possible explanation for the increase in CO-MRSA 
could be a rise in outpatient antimicrobial drug use. Com-
pared with other European countries (average 20 deﬁ  ned 
daily doses [DDD]/1,000 inhabitants/day) and the United 
States (26 DDD/1,000 inhabitants/day), Denmark had a 
low level of antimicrobial drug use in 2004 (14 DDD/1,000 
inhabitants/day) (30). Although the use of systemic antimi-
crobial agents in Denmark has increased 14.7% from 2000 
through 2004 (www.dfvf.dk/ﬁ  les/ﬁ  ler/zoonosecentret/pub-
likationer/danmap/danmap_2004.pdf), it is unlikely that 
this is the only reason for the rise in MRSA.
Although we found a high number of CO-MRSA, our 
assessment of risk factors has some limitations. Having the 
data of all hospital admissions and outpatient hospital visits 
from the NHCD makes the division into the categories of 
HA-MRSA and CO-MRSA almost certain. However, be-
cause most of the patients were not directly interviewed 
about risk factors, some data might have been missed. 
Therefore, some of the CO-NR MRSA might actually be 
CO-CR or CO-HCA MRSA.
Previous guidelines used in Denmark for controlling 
MRSA in the hospitals by screening patients transferred 
from hospitals abroad are not sufﬁ  cient to address today’s 
CO-MRSA problems. In November 2006, the Danish 
National Health Board published national guidelines for 
preventing MRSA spread (www.sst.dk/publ/publ2006/cff/
mrsa/vejl_mrsa.pdf). These guidelines introduce new ap-
proaches to limit the spread of MRSA in hospitals and in 
the community, where isolation of patients is not an op-
tion. In some hospitals we now have introduced admittance 
MRSA screening of all patients who have wounds or urinary 
catheters and we are isolating all residents from MRSA-en-
demic nursing homes. The hospital infection control teams 
see all patients with MRSA. In the community we have 
improved the screening of close contacts of MRSA patients 
and initiated a task force that visits patients at home and 
plans the eradication of MRSA carriage for all persons in 
the household. Our initial regime is 5 days’ treatment with 
4% chlorhexidine body wash once a day and 2% mupiro-
cin nasal ointment 3× each day combined with washing 
of towels and bed linen and improved housekeeping. For 
some patients the treatment needs to be repeated (31), and 
patients with MRSA carriage that is difﬁ  cult to eradicate 
are sometimes treated with systemic antimicrobial agents 
(32). Unfortunately, not all patients are decolonized by this 
procedure, and the long-term effect of eradication treat-
ment, including the possible development of resistance to 
the antimicrobial agents used, is not well documented (33). 
Long-term studies on new and more effective methods to 
eradicate MRSA carriage are needed.
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The rapid increase and genetic diversity of CO-MRSA 
in a country with low prevalence of HA-MRSA are of great 
concern, as these CO-MRSA are sporadically appearing in 
our hospitals. Especially worrisome is the discovery that 
MRSA USA300 genotype is in our community, as this 
MRSA has recently shown its epidemic potential in both 
the US community and US hospitals (24). MRSA isolation 
rates are increasing in other Nordic countries (34,35), but 
we need more data on CO-MRSA from countries in which 
classic HA-MRSA dominate. The current search-and-de-
stroy policies need to be updated, reﬁ  ned, and intensiﬁ  ed 
if Denmark hopes to remain a country with low MRSA 
prevalence.
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